16 May 2016 - Deborah Wilkes
Archived
Perrigo recorded an impairment charge of US$467 million related to its Branded Consumer Healthcare business – formerly the Omega Pharma European OTC business – in the first quarter of 2016. As a result, Perrigo reported a net loss of US$335 million in the three months.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.